Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma.

[1]  V. Bronte,et al.  Myeloid-derived suppressor cell heterogeneity and subset definition. , 2010, Current opinion in immunology.

[2]  H. Ueno,et al.  Harnessing Dendritic Cells to Generate Cancer Vaccines , 2009, Annals of the New York Academy of Sciences.

[3]  Martin A. Cheever,et al.  The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research , 2009, Clinical Cancer Research.

[4]  D. Klatzmann,et al.  Tumor emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumors in mice. , 2009, The Journal of clinical investigation.

[5]  S. Steinberg,et al.  Interferon regulatory factor-8 modulates the development of tumour-induced CD11b+Gr-1+ myeloid cells , 2009, Journal of cellular and molecular medicine.

[6]  A. Hauschild,et al.  Immunotherapy of distant metastatic disease , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  L. Kumar,et al.  Sustained Remission Achieved With ATRA and Chemotherapy in Second Relapse of Acute Promyelocytic Leukemia in Down Syndrome , 2009, Journal of pediatric hematology/oncology.

[8]  A. Poliakov,et al.  Induction of myeloid‐derived suppressor cells by tumor exosomes , 2009, International journal of cancer.

[9]  F. Bertucci,et al.  Distant metastasis: not out of reach any more , 2009, Journal of biology.

[10]  C. Divino,et al.  The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. , 2009, Cancer research.

[11]  B. Rini,et al.  Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients , 2009, Clinical Cancer Research.

[12]  Hongxiang Sun,et al.  Advances in saponin-based adjuvants. , 2009, Vaccine.

[13]  Srinivas Nagaraj,et al.  Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.

[14]  K. Anderson.  Tumor Vaccines for Breast Cancer , 2009, Cancer investigation.

[15]  C. Melief.  Cancer immunotherapy by dendritic cells. , 2008, Immunity.

[16]  S. Steinberg,et al.  Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines , 2008, Clinical Cancer Research.

[17]  S. H. Kim,et al.  Mage-b vaccine delivered by recombinant Listeria monocytogenes is highly effective against breast cancer metastases , 2008, British Journal of Cancer.

[18]  Craig Murdoch,et al.  The role of myeloid cells in the promotion of tumour angiogenesis , 2008, Nature Reviews Cancer.

[19]  M. Manns,et al.  A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. , 2008, Gastroenterology.

[20]  T. Ichim,et al.  Selective apoptosis of breast cancer cells by siRNA targeting of BORIS. , 2008, Biochemical and biophysical research communications.

[21]  V. Bronte,et al.  Tumor‐induced tolerance and immune suppression by myeloid derived suppressor cells , 2008, Immunological reviews.

[22]  Victor V Lobanenkov,et al.  BORIS, a paralogue of the transcription factor, CTCF, is aberrantly expressed in breast tumours , 2008, British Journal of Cancer.

[23]  B. Chauffert,et al.  Increase of CD4+CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+CD25+ T lymphocytes , 2007, Clinical and experimental immunology.

[24]  J. Fallon,et al.  Rejection of metastatic 4T1 breast cancer by attenuation of Treg cells in combination with immune stimulation. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[25]  R. Steinman,et al.  Taking dendritic cells into medicine , 2007, Nature.

[26]  A. Ribas.  Anti-CTLA4 Antibody Clinical Trials in Melanoma. , 2007, Update on cancer therapeutics.

[27]  V. Noskov,et al.  Evolutionary Diversification of SPANX-N Sperm Protein Gene Structure and Expression , 2007, PloS one.

[28]  Victor V Lobanenkov,et al.  Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant , 2006, Journal of cellular biochemistry.

[29]  B. Ludewig,et al.  Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma , 2006, Cancer Immunology, Immunotherapy.

[30]  T. Waldmann.  Effective cancer therapy through immunomodulation. , 2006, Annual review of medicine.

[31]  J. Leips,et al.  Inflammation Induces Myeloid-Derived Suppressor Cells that Facilitate Tumor Progression1 , 2006, The Journal of Immunology.

[32]  E. Gilboa,et al.  Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. , 2005, The Journal of clinical investigation.

[33]  Victor V Lobanenkov,et al.  Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. , 2005, Cancer research.

[34]  Victor V Lobanenkov,et al.  Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes. , 2005, Cancer research.

[35]  Lloyd J. Old,et al.  Cancer/testis antigens, gametogenesis and cancer , 2005, Nature Reviews Cancer.

[36]  W. Overwijk.  Breaking tolerance in cancer immunotherapy: time to ACT. , 2005, Current opinion in immunology.

[37]  S. Rosenberg,et al.  Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.

[38]  Mark Shackleton,et al.  Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[39]  T. Kieber‐Emmons,et al.  Strategies in cancer vaccines development. , 2003, International journal for parasitology.

[40]  J. Berzofsky,et al.  Resistance to Metastatic Disease in STAT6-Deficient Mice Requires Hemopoietic and Nonhemopoietic Cells and Is IFN-γ Dependent1 , 2002, The Journal of Immunology.

[41]  Victor V Lobanenkov,et al.  The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer. , 2002, Seminars in cancer biology.

[42]  P. Hwu,et al.  Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells. , 2002, The Journal of clinical investigation.

[43]  J. J. Breen,et al.  BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[44]  J. Trapani,et al.  A fresh look at tumor immunosurveillance and immunotherapy , 2001, Nature Immunology.

[45]  R. Offringa,et al.  Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model. , 2000, Cancer research.

[46]  S. Ostrand-Rosenberg,et al.  Mouse 4T1 Breast Tumor Model , 2000, Current protocols in immunology.

[47]  B A Pulaski,et al.  Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model. , 2000, Cancer research.

[48]  J. Kaplan,et al.  Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. , 1999, Journal of immunology.

[49]  P. Coulie,et al.  Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1 , 1999, International journal of cancer.

[50]  S. Ostrand-Rosenberg,et al.  Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. , 1998, Cancer research.

[51]  E. Rutgers,et al.  Follow‐up after treatment of primary breast cancer , 1989, The British journal of surgery.

[52]  F. Miller,et al.  Quantitative selectivity of contact-mediated intercellular communication in a metastatic mouse mammary tumor line. , 1983, Cancer research.

[53]  L. Arrighi,et al.  [Treatment of breast cancer]. , 1971, Prensa medica argentina.

[54]  Victor V Lobanenkov,et al.  DNA, but not protein vaccine based on mutated BORIS antigen significantly inhibits tumor growth and prolongs the survival of mice , 2008, Gene Therapy.

[55]  M. Nishimura,et al.  Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy , 2008, Cancer Immunology, Immunotherapy.

[56]  K. Odunsi,et al.  DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer. , 2007, Cancer immunity.

[57]  D. Gabrilovich,et al.  Immune tolerance in breast cancer. , 2004, Breast disease.

[58]  A. Simpson,et al.  The cancer/testis genes: review, standardization, and commentary. , 2004, Cancer immunity.

[59]  P. Srivastava,et al.  Immunization against a dominant tumor antigen abrogates immunogenicity of the tumor. , 2002, Cancer immunity.

[60]  E. Coligan.  Current protocols in immunology , 1991 .

[61]  W. Donegan,et al.  Screening for recurrent breast cancer--its effectiveness and prognostic value. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.